Deferasirox for managing transfusional iron overload in people with sickle cell disease

BACKGROUND: Sickle cell disease (SCD) is a group of genetic haemoglobin disorders, that occurs in about 2.2 per 1000 births worldwide. Increasingly, some people with SCD develop secondary iron overload due to occasional red blood cell transfusions or are on long‐term transfusion programmes for e.g....

Full description

Saved in:
Bibliographic Details
Published in:Cochrane Database Syst Rev
Main Authors: Meerpohl, Joerg J, Schell, Lisa K, Rücker, Gerta, Motschall, Edith, Fleeman, Nigel, Niemeyer, Charlotte M, Bassler, Dirk
Format: Artigo
Language:Inglês
Published: John Wiley & Sons, Ltd 2014
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6489379/
https://ncbi.nlm.nih.gov/pubmed/24893174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD007477.pub3
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items